Vasoactive Intestinal Peptide (VIP): Research, Receptors, and What Recent Studies Show

Key takeaways

• VIP is a 28-amino-acid neuropeptide with wide effects in the gut, immune system, lungs, and brain.
• VIP signals mainly through VPAC1 and VPAC2 receptors and can shift cells toward anti-inflammatory behavior.
• Recent research shows VIP can promote intestinal regeneration after irradiation injury and support secretory cell differentiation in organoids.
• Other recent work points in the opposite direction for cancer: VIP receptor antagonists can boost T-cell activity and anti-leukemia responses in mice.

Vasoactive intestinal peptide, or VIP, is a small peptide with a large research footprint. It was first characterized in 1970 and originally noted for its strong vasodilatory effects. Since then, studies have linked VIP to gut motility, secretion, immune control, epithelial renewal, circadian timing, and disease models in cancer, allergy, and inflammation. Recent papers continue to show that VIP is not a single-purpose molecule. It acts more like a broad signal that can push different tissues toward different outcomes, depending on the receptor, cell type, and disease context.

That is why VIP remains important in research settings. In some models, it appears to reduce inflammation and support tissue repair. In others, especially in cancer biology, VIP signaling may help immune evasion. The newest literature reflects that split view clearly.

What VIP is and where it acts

VIP is a 28-amino-acid neuropeptide in the secretin/glucagon superfamily. It is widely distributed in the central and peripheral nervous systems, and it is also found in digestive, respiratory, reproductive, and cardiovascular tissues. One review describes VIP as a pleiotropic regulator with anti-inflammatory, bronchodilatory, neuroprotective, chronobiotic, and immunomodulatory functions. That broad role is one reason it shows up across so many disease models.

Receptors and signaling

VIP signals through two main G-protein-coupled receptors: VPAC1 and VPAC2. These receptors are expressed in tissues including the hypothalamus, lung, small intestine, immune cells, pituitary gland, and vascular smooth muscle. In the immune system, VIP signaling has been tied to reduced NF-kB activation and lower production of inflammatory mediators such as IL-6, TNF-alpha, IL-12, and MMP-9, while supporting IL-10 and TGF-beta1-related regulatory signaling. In another study, VIP reduced CREB phosphorylation, which is a downstream pathway of the VIP receptor.

Those details matter because VIP biology is receptor-driven. The same peptide can have different effects in different tissues depending on how strongly those receptors are expressed and how the downstream signaling is wired.

A broad tissue profile

Recent reviews and studies place VIP in several systems at once:

• In the gut, it affects secretion, motility, nutrient handling, and epithelial turnover.
• In the immune system, it supports immune tolerance and can push cells toward a regulatory state.
• In the lungs, it is described as a major endogenous bronchodilator and pulmonary vasodilator.
• In the hypothalamus, it is linked to circadian rhythm entrainment and sleep-wake timing.

That breadth makes VIP useful to study, but it also makes simple claims about it risky. The better question is not whether VIP is “good” or “bad.” The better question is what VIP is doing in a specific model.

VIP and immune balance

Several of the sources emphasize VIP as an endogenous anti-inflammatory neuropeptide. One review states that VIP helps maintain immune tolerance in two main ways: by balancing pro-inflammatory and anti-inflammatory factors, and by inducing regulatory T cells with suppressive activity against autoreactive T cell effectors. Another review describes VIP as a major immunoregulatory neuropeptide that is synthesized not only by neurons but also by immune cells.

This immune effect is one of the most studied parts of VIP biology. In the literature provided, VIP is connected with immune deviation, tolerogenic dendritic cells, and T cell differentiation. These are not abstract concepts. They are core immune control points. If VIP shifts antigen-presenting cells and T cells toward a more regulatory state, that could matter in autoimmunity and chronic inflammation.

What the literature supports

The evidence in the bundle supports several specific immune-related statements:

• VIP can suppress inflammatory cytokine production in immune cells.
• VIP can promote regulatory T cell development.
• VIP is associated with tolerogenic immune signaling rather than purely pro-inflammatory signaling.
• VIP receptors are present on T cells, macrophages, and dendritic cells.

The sources do not support a claim that VIP will improve every immune condition. Instead, they show that VIP is a regulator whose effect depends on the model. In one context, it may help restrain harmful inflammation. In another, such as cancer, its signaling may protect diseased cells or suppress anti-tumor immunity.

Cross-links in immune research

VIP is often discussed alongside other immune-linked peptides such as Thymosin Alpha-1 and BPC-157 in broader peptide research. Those are different molecules with different evidence bases, but they sit in the same research neighborhood of immune and tissue signaling.

VIP in the gut and intestinal repair

The gut is one of VIP’s best-established research settings. One review calls VIP a gut peptide hormone first reported as a vasodilator in 1970. That review also connects VIP to ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms. Another study in organoids and mice adds newer detail on epithelial homeostasis and repair.

Secretory differentiation and regeneration

In the intestinal study, VIP promoted epithelial differentiation toward a secretory phenotype, mainly through the p38 MAPK pathway. The researchers also found that VIP affected epithelial proliferation and the number and proliferative activity of Lgr5-EGFP+ progenitor cells under homeostatic conditions. In injury settings, those progenitor cells became more sensitive to VIP-related changes.

The most concrete result was in irradiation injury. Jejunal organoids were exposed to 6 Gy of irradiation in vitro, and mice received 12 Gy of abdominal irradiation in vivo followed by intraperitoneal VIP. In both settings, VIP promoted regeneration and mitigated injury. That is a specific and useful finding. It shows that VIP is not just an inflammatory signal. It can also support recovery in damaged intestinal tissue.

Why this matters

The gut findings fit with the older literature on VIP as a regulator of epithelial and endocrine function. They also show that tissue context matters. Under baseline conditions, VIP influenced stem and progenitor cell behavior. Under injury conditions, it helped push the tissue toward repair. That does not mean VIP is a general healing peptide. It means its effect depends on the biological state of the tissue.

For researchers, that distinction is important. A molecule that supports secretory differentiation and regeneration in irradiated jejunal tissue may not behave the same way in inflammation, cancer, or other organ systems.

VIP is often grouped with other gut-active peptides such as GLP-1 in broad digestive research discussions, but VIP has its own receptor biology and its own tissue effects.

VIP in cancer: agonist and antagonist stories

Cancer research around VIP is more complicated than the gut and immune literature. The bundle includes two different directions. Older and review literature describe VIP as involved in cancer proliferation and immune suppression. The newest paper shifts attention to VIP receptor antagonists as possible immunotherapy tools for acute myeloid leukemia, or AML.

Why antagonists matter

The 2026 study screened a combinatorial library of VIPhyb C-terminal peptide sequence variants to find a more potent VIP receptor antagonist. The goal was straightforward: improve on the limited potency of the original antagonist peptide, VIPhyb, in T-cell activation and murine anti-leukemia models.

The researchers used in silico screening first. Their docking analyses identified sequences with predicted increased binding affinity to human VIP receptors VPAC1 and VPAC2. They then synthesized 15 peptides and tested them in purified mouse and human T cells, plus murine AML models.

Key findings from the leukemia study

The study reports several concrete findings:

• Daily subcutaneous injections of VIP receptor antagonist peptides induced anti-leukemia responses in C57Bl/6 mice engrafted with the C1498 leukemia cell line.
• Predicted receptor binding correlated positively with mouse T-cell proliferation and anti-leukemia activity.
• ANT308 and ANT195 emerged as top candidates.
• ANT308 decreased CREB phosphorylation and stimulated granzyme B and perforin expression in CD8+ T cells from AML patients.

Those are meaningful mechanistic results. They suggest that blocking VIP signaling may remove a brake on T-cell activity in at least some leukemia settings. The study’s authors frame the work as a step toward novel immunotherapies for relapsed AML.

How to read the cancer data carefully

This does not mean VIP is uniformly pro-cancer in every setting. It does mean that VIP signaling can support immune suppression in ways that are relevant to leukemia models. The research also shows that antagonism, not stimulation, may be the useful approach in some cancer contexts. That is a good example of why peptide biology cannot be reduced to a single direction of effect.

Other systems: lungs, brain, and circadian timing

The provided sources also place VIP in the lungs and nervous system. One clinic reference describes VIP as the primary endogenous bronchodilator and pulmonary vasodilator in the lungs, produced by non-adrenergic non-cholinergic neurons. It also notes that VIP is linked with pulmonary arterial hypertension and airway hyperresponsiveness in VIP-deficient states. Another source links VIP to circadian rhythm entrainment through the suprachiasmatic nucleus in the hypothalamus.

These statements fit the broader picture from the reviews: VIP is a neuromodulator with endocrine and immune effects. The bundle does not provide fresh experimental data on these systems beyond the general descriptions, so it is safest to treat them as established background rather than new conclusions.

The 2026 PubMed listings in the bundle also point to newer work in the hippocampus and in myopia, but the provided snippets do not include enough detail to support specific claims from those studies here.

What researchers should keep in mind

VIP is not a simple one-pathway peptide. It acts through VPAC1 and VPAC2, affects many tissues, and can shift biology in different directions based on context. The strongest supported themes in the research bundle are these:

• VIP supports immune tolerance and regulatory signaling in many models.
• VIP promotes intestinal secretory differentiation and repair after irradiation injury.
• VIP receptor antagonism can improve T-cell activity and anti-leukemia responses in AML models.
• VIP is widely distributed and likely does different things in different organs.

That means any serious research discussion should separate mechanism from application. A finding in jejunal organoids does not automatically translate to cancer therapy. A leukemia antagonist does not automatically overturn VIP’s anti-inflammatory role in other systems. The evidence supports a context-specific view.

It also means protocol language should stay precise. If a paper reports 6 Gy in organoids and 12 Gy in mice, that should be stated exactly. If a paper finds two top candidates, ANT308 and ANT195, that detail matters. VIP research is increasingly mechanistic, and the details carry the meaning.

FAQ

What is VIP?

VIP stands for vasoactive intestinal peptide. It is a 28-amino-acid neuropeptide in the secretin/glucagon superfamily. It was first characterized in 1970 and is found in the nervous system and many peripheral tissues.

What receptors does VIP use?

VIP mainly signals through two receptors: VPAC1 and VPAC2. These are G-protein-coupled receptors found in tissues such as the hypothalamus, lung, small intestine, immune cells, pituitary gland, and vascular smooth muscle.

Is VIP anti-inflammatory?

In many of the provided studies and reviews, yes. VIP is described as an anti-inflammatory neuropeptide that can reduce inflammatory signaling and support regulatory T cell development. But its effects depend on context, and in cancer biology VIP signaling may also support immune suppression.

What did the newest intestinal study show?

The study found that VIP promoted epithelial differentiation toward a secretory phenotype through the p38 MAPK pathway. It also supported intestinal regeneration after irradiation injury in organoids and in mice given 12 Gy abdominal irradiation.

Why are VIP receptor antagonists being studied in leukemia?

Because blocking VIP signaling may remove an immune brake. In a murine AML model, daily subcutaneous VIP receptor antagonist peptides induced anti-leukemia responses, and the candidates ANT308 and ANT195 showed strong activity. ANT308 also lowered CREB phosphorylation and increased granzyme B and perforin in CD8+ T cells from AML patients.